Victory Square Technologies Inc (TSE:VST) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Victory Square Technologies Inc. expands its medical offerings through Hydreight Technologies with the addition of Tirzepatide, enhancing their weight loss portfolio that already includes GLP-1 injections. This move aims to provide cost-effective diabetes and weight loss treatments across the US, leveraging a robust network of over 3,000 nurses and 107 white-label locations. Tirzepatide, an FDA-approved medicine for type 2 diabetes, is recognized for its weight loss benefits and will now be available in over 700 cities nationwide.
For further insights into TSE:VST stock, check out TipRanks’ Stock Analysis page.